Recombinant Human Keratinocyte Growth Factor

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Amgen, University of Michigan

Conditions

Acute Graft Versus Host DiseaseGraft Versus Host DiseaseStomatitis

Phase 1

Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

TerminatedNCT00038792

M.D. Anderson Cancer CenterAcute Graft Versus Host Disease

Start: 2000-10-31End: 2003-01-31Updated: 2012-08-02

Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

CompletedNCT00056875

University of MichiganGraft Versus Host Disease

Start: 2002-09-30End: 2005-06-30Target: 50Updated: 2015-03-25

Phase 3

Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

CompletedNCT00041665

AmgenStomatitis

Updated: 2013-05-08